Literature DB >> 11045299

The spectrum of peritoneal fibrosing syndromes in peritoneal dialysis.

R A Mactier1.   

Abstract

A variable degree of diffuse peritoneal fibrosis has been documented in all patients who have been on long-term peritoneal dialysis. Peritoneal dialysis-induced diffuse peritoneal fibrosis varies from opacification and "tanning" of the peritoneum, which may have only a moderate detrimental effect on peritoneal transport kinetics, to a progressive, sclerosing encapsulating peritonitis (SEP), which may lead to cessation of peritoneal dialysis and to death. Fewer than 1% of peritoneal dialysis patients develop overt SEP as manifested by combinations of intestinal obstruction, weight loss, and ultrafiltration failure. The diagnosis of SEP depends on a combination of laparotomy and radiological features in suspected cases and consequently the true incidence of SEP is most likely underestimated. Several predisposing, interrelated risk factors for both peritoneal fibrosis and sclerosing encapsulating peritonitis have been identified: prolonged duration of peritoneal dialysis, history of severe or recurrent episodes of peritonitis, and higher exposure to hypertonic glucose-based dialysis solutions. Nevertheless, the etiology of SEP is unknown and several causal factors may simultaneously or sequentially initiate and maintain a low-grade serositis that leads to uncontrolled fibroneogenesis. The high mortality rate of SEP has emphasized the need to develop preventive strategies. These strategies include early peritoneal catheter removal to avoid refractory peritonitis, the development of more biocompatible dialysis solutions, restriction of the use of hypertonic glucose-based dialysis solutions during and after episodes of peritonitis, and, perhaps, limiting the duration of peritoneal dialysis in at-risk patients. This approach was followed in a Japanese unit where a subgroup of all patients who had been on peritoneal dialysis for more than 5 years and who had poor ultrafiltration and peritoneal calcification on computed tomography (CT) scan were shown to have peritoneal sclerosis on peritoneal biopsy and were therefore electively transferred to hemodialysis. This acquired spectrum of peritoneal fibrosing syndromes leads to long-term complications in peritoneal dialysis, whereas localized fibrous adhesions secondary to prior abdominal surgery may prevent the successful initiation of peritoneal dialysis.

Entities:  

Mesh:

Year:  2000        PMID: 11045299

Source DB:  PubMed          Journal:  Adv Perit Dial        ISSN: 1197-8554


  7 in total

Review 1.  Idiopathic sclerosing encapsulating peritonitis: abdominal cocoon.

Authors:  Jenny N Tannoury; Bassam N Abboud
Journal:  World J Gastroenterol       Date:  2012-05-07       Impact factor: 5.742

2.  Pharmacology of sclerotherapy.

Authors:  Giustino Albanese; Kimi L Kondo
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

3.  Adipose tissue behavior is distinctly regulated by neighboring cells and fluid flow stress: a possible role of adipose tissue in peritoneal fibrosis.

Authors:  Shigehisa Aoki; Kazuma Udo; Hiroyuki Morimoto; Satoshi Ikeda; Toshiaki Takezawa; Kazuyoshi Uchihashi; Aki Nishijima-Matsunobu; Mitsuru Noguchi; Hajime Sugihara; Shuji Toda
Journal:  J Artif Organs       Date:  2013-03-24       Impact factor: 1.731

Review 4.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

5.  Attenuation of methylglyoxal-induced peritoneal fibrosis: immunomodulation by interleukin-10.

Authors:  Akira Onishi; Tetsu Akimoto; Masashi Urabe; Ichiro Hirahara; Shigeaki Muto; Keiya Ozawa; Daisuke Nagata; Eiji Kusano
Journal:  Lab Invest       Date:  2015-09-14       Impact factor: 5.662

6.  Encapsulating peritoneal sclerosis caused by cell-free and concentrated ascites reinfusion therapy: a case report.

Authors:  Hideya Itagaki; Suzuki Katuhiko
Journal:  J Med Case Rep       Date:  2021-02-06

7.  Astragalus membranaceus inhibits peritoneal fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-β1 (TGF-β1) pathway in rats submitted to peritoneal dialysis.

Authors:  Zhenghong Li; Lu Zhang; Weiming He; Changle Zhu; Jinsong Yang; Meixiao Sheng
Journal:  Int J Mol Sci       Date:  2014-07-22       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.